Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 20, 2013

View Archived Issues

Quantitative, non-invasive, magnetic resonance imaging of tumor metabolism in vivo

Identification of a novel clinical biomarker for a specific subset of patients with breast cancer

Phase I clinical evaluation of a sporozoite-based vaccine for immunization against malaria

LIDDS reports data from second phase IIa study of Liproca Depot

Researchers highlight the relevance of BAP1 mutations in melanoma

Retrophin to exclusively negotiate development rights for autism and schizophrenia treatment

Retrophin reports RE-024 preclinical results

FDA approves GSK's FluLaval Quadrivalent influenza virus vaccine

Australian government provides grant to Aeras for tuberculosis vaccine

New MGAT2 inhibitors for hypertriglyceridemia presented by Eli Lilly

Taiho Pharmaceutical designs novel agents for urinary incontinence

Selexys commences with SUSTAIN phase II trial

Roche and Genentech disclose new MEKKK4 inhibitors

Actelion synthesizes new chemokine CXCR3 receptor modulators

French authorities grant market access to Pixuvri for aggressive non-Hodgkin's lymphoma

Toyama Chemical Co. presents novel products for HIV infection

Tau Therapeutics collaborator receives grant for glioblastoma reserach

BIND Therapeutics initiates dosing in phase II PSMA-targeting study

GenSpera raises funds for G-202 development

to-BBB to proceed to phase IIa 2B3-101 study

GTx' POWER trials fail to meet primary endpoints

Wanbang Pharma to develop Sirona Biochem's SGLT2 inhibitor in China

FDA approves Trokendi XR launch

Japanese researchers divulge new tubulin polymerization inhibitors

Japanese authorities approve Bayer's Stivarga for GIST

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...